Back to Agenda
SESSION 4: Sample Management
Session Chair(s)
Neveen Kamel
Regulatory Affairs Head North Africa, Egypt & French-speaking Africa, Merck Group, Egypt
Zainab Aziz, MSC, RPH
Associate Director- Regulatory Policy MEA, Novartis, South Africa
Overview: This session will explore challenges associated with sample provision for Post-Approval Changes and promote best practices in Sample Management, leveraging Reliance pathways. The session will also highlight the development of a unified laboratory framework for sample testing through the Network of African Reliance Laboratories (NARL), the growing importance of post-marketing surveillance, share effective risk management strategies for product release post-importation and emphasise capacity building for local laboratories to detect substandard and falsified medicines.
Speaker(s)
Zainab Aziz, MSC, RPH
Associate Director- Regulatory Policy MEA, Novartis, South Africa
Streamlining Sample Management to Strengthen Health Outcomes in Africa
Joerg Garbe, PHD, MSC
IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland
Reliance Frees up Capacity for Efficient Post-Marketing Surveillance of Medicines
Neven Ahmed
Reliance team leader, Egyptian Drug Authority (EDA), Egypt
Sample Management in the Context of Reliance for NDA and PACs
Noha Mohamed Reda Arram
Head of Drug Quality Control Laboratory - Pharmacy & Drug Control Department, Ministry of Public Health (MOPH), Qatar, Qatar
Sample Management overview – Qatar Experience
Assane Coulibaly
CEO / Director General, Autorité Ivoirienne de Régulation Pharmaceutique (AIRP) / Ivorian Pharm RA, Côte d'Ivoire
Panel Discussion with Q&A (With the additional participation of):
Have an account?